Novel Regimens Yield High Response Rates for Older, Hodgkin Lymphoma Patients
Older patients with classical Hodgkin lymphoma unsuitable for conventional chemotherapy had high rates of durable responses with two brentuximab vedotin (BV; Adcetris) regimens, one that omitted chemotherapy, a small prospective study showed. Brentuximab plus the alkylating agent dacarbazine (DTIC) produced an objective response rate (ORR) of 95% in 22 patients, whereas brentuximab plus nivolumab (Opdivo) […]
Physicists watch as ultracold atoms form a crystal of quantum tornadoes: The new observations record a key crossover from classical to quantum behavior.
The world we experience is governed by classical physics. How we move, where we are, and how fast we’re going are all determined by the classical assumption that we can only exist in one place at any one moment in time. But in the quantum world, the behavior of individual atoms is governed by the […]
Early Promise for Pembrolizumab Plus Chemo in RR Hodgkin’s Lymphoma
A chemoimmunotherapy regimen led to a 100% response rate as second-line therapy for relapsed/refractory (RR) classical Hodgkin lymphoma (cHL), a small phase II trial showed. All 38 evaluable patients achieved objective responses with the combination of pembrolizumab (Keytruda), gemcitabine, vinorelbine, and liposomal doxorubicin (P-GVD), including complete responses in 36 of 38 cases. All but two […]